Amacron Does Not Present a Grave Danger

Amicron is associated with a two thirds reduction in the risk of coved 19 hospitalization when compared to delta. It replicates far more efficiently in the bronchus and upper respiratory tract than delta, but less efficiently in the lungs. And then finally, they return to data out of south africa, which shows the case numbers peking at about 97 % of the delta wave.